|
🐜
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
27 auth.
V. Heinemann,
L. V. von Weikersthal,
T. Decker,
A. Kiani,
U. Vehling‐Kaiser,
S. Al-Batran,
T. Heintges,
C. Lerchenmüller,
C. Kahl,
G. Seipelt,
F. Kullmann,
M. Stauch,
W. Scheithauer,
Jörg Hielscher,
M. Scholz,
...
S. Müller,
H. Link,
N. Niederle,
A. Rost,
H. Höffkes,
M. Moehler,
R. U. Lindig,
D. Modest,
Lisa Rossius,
T. Kirchner,
A. Jung,
S. Stintzing
|
10 |
2014 |
10
🐜
|
|
🐜
|
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
29 auth.
Y. Janjigian,
K. Shitara,
M. Moehler,
M. Garrido,
P. Salman,
L. Shen,
L. Wyrwicz,
K. Yamaguchi,
T. Skoczylas,
A. Bragagnoli,
Tianshu Liu,
M. Schenker,
P. Yánez,
M. Tehfé,
R. Kowalyszyn,
...
M. Karamouzis,
R. Brugés,
T. Zander,
R. Pazo-Cid,
E. Hitre,
K. Feeney,
J. Cleary,
V. Poulart,
D. Cullen,
M. Lei,
H. Xiao,
K. Kondo,
Mingshun Li,
J. Ajani
|
10 |
2021 |
10
🐜
|
|
🐜
|
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
57 auth.
S. Al-Batran,
N. Homann,
C. Pauligk,
T. Goetze,
J. Meiler,
S. Kasper,
H. Kopp,
F. Mayer,
G. Haag,
K. Luley,
U. Lindig,
W. Schmiegel,
M. Pohl,
J. Stoehlmacher,
G. Folprecht,
...
S. Probst,
N. Prasnikar,
W. Fischbach,
R. Mahlberg,
J. Trojan,
M. Koenigsmann,
U. Martens,
P. Thuss-Patience,
M. Egger,
A. Block,
V. Heinemann,
G. Illerhaus,
M. Moehler,
M. Schenk,
F. Kullmann,
D. Behringer,
M. Heike,
D. Pink,
C. Teschendorf,
Carmen Löhr,
H. Bernhard,
G. Schuch,
V. Rethwisch,
L. F. V. Weikersthal,
J. Hartmann,
M. Kneba,
S. Daum,
K. Schulmann,
J. Weniger,
S. Belle,
T. Gaiser,
F. Oduncu,
M. Güntner,
W. Hozaeel,
Alexander Reichart,
E. Jäger,
T. Kraus,
S. Mönig,
W. Bechstein,
M. Schuler,
H. Schmalenberg,
R. Hofheinz
|
10 |
2019 |
10
🐜
|
|
🐜
|
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
153 auth.
K. Shitara,
M. Özgüroğlu,
Y. Bang,
M. Di Bartolomeo,
M. Mandalà,
M. Ryu,
L. Fornaro,
T. Olesiński,
C. Caglevic,
H. Chung,
K. Muro,
E. Goekkurt,
W. Mansoor,
R. McDermott,
E. Shacham-Shmueli,
...
Xinqun Chen,
C. Mayo,
S. Kang,
A. Ohtsu,
C. Fuchs,
G. Lerzo,
J. O'Connor,
G. Mendez,
J. Lynam,
N. Tebbutt,
M. Wong,
A. Strickland,
C. Karapetis,
D. Goldstein,
P. Vasey,
J. Van Laethem,
E. Van Cutsem,
S. Berry,
M. Vincent,
Bettina Muller,
F. Rey,
A. Zambrano,
J. Guerra,
M. Krogh,
L. Baeksgaard,
M. Yilmaz,
A. Elme,
Andrus Magi,
P. Auvinen,
T. Alanko,
M. Moehler,
V. Kunzmann,
T. Seufferlein,
P. Thuss-Patience,
T. Hoehler,
G. Haag,
S. Al-Batran,
H. Castro,
K. Lopez,
Mynor Aguilar Vasquez,
Mario Sandoval,
K. Lam,
S. Cuffe,
C. Kelly,
R. Geva,
A. Hubert,
A. Beny,
B. Brenner,
Aprile Giuseppe,
A. Falcone,
E. Maiello,
R. Passalacqua,
V. Montesarchio,
H. Hara,
K. Chin,
T. Nishina,
Y. Komatsu,
N. Machida,
S. Hironaka,
T. Satoh,
T. Tamura,
Naotaoshi Sugimoto,
Haruhiko Cho,
Yashushi Omuro,
Ken Kato,
M. Goto,
I. Hyodo,
Kazuhiro Yoshida,
H. Baba,
T. Esaki,
J. Furuse,
Wan Zamaniah Wan Mohammed,
Carlos Hernandez Hernandez,
Juan Casas Garcia,
Adriana Dominguez Andrade,
Katriona Clarke,
G. Hjortland,
N. Glenjen,
T. Kubiatowski,
J. Jacek,
M. Wojtukiewicz,
S. Lazarev,
Yuri Lancukhay,
Sergey Afanasayev,
V. Moiseyenko,
V. Kostorov,
S. Protsenko,
V. Shirinkin,
D. Sakaeva,
N. Fadeeva,
W. Yong,
C. Ng,
B. Robertson,
B. Rapaport,
G. Cohen,
L. Dreosti,
P. Ruff,
C. Jacobs,
G. Landers,
W. Szpak,
S. Roh,
Jeeyun Lee,
Yeul-Hong Kim,
H. Chung,
Maria Alsina Maqueda,
F. Longo Muñoz,
Andres Cervantes Aguilar,
Enrique Aranda Aguilar,
P. García Alfonso,
F. Rivera,
Jaime Feliu Batle,
R. Pazo Cid,
K. Yeh,
Jen‐Shi Chen,
Y. Chao,
C. Yen,
O. Kara,
Ş. Yalçın,
D. Hochhauser,
I. Chau,
A. Benson,
V. Shankaran,
W. Shaib,
P. Philip,
V. Sharma,
R. Siegel,
Weijing Sun,
Z. Wainberg,
B. George,
A. Bullock,
S. Myrick,
Josephine Faruol,
Richard Siegel,
T. Larson,
C. Becerra,
Suresh Ratnam,
D. Richards,
Stephen L. Riche
|
9 |
2018 |
9
🐜
|
|
🐢
|
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
27 auth.
R. Kelly,
J. Ajani,
J. Kużdżał,
T. Zander,
E. Van Cutsem,
G. Piessen,
G. Mendez,
J. Feliciano,
S. Motoyama,
A. Lièvre,
H. Uronis,
E. Elimova,
C. Grootscholten,
K. Geboes,
S. Zafar,
...
S. Snow,
A. Ko,
K. Feeney,
M. Schenker,
Piotr Kocoń,
Jenny Zhang,
Lili Zhu,
M. Lei,
Prianka Singh,
K. Kondo,
J. Cleary,
M. Moehler
|
9 |
2021 |
9
🐢
|
|
🐢
|
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
16 auth.
F. Lordick,
Yoon-Koo Kang,
H. Chung,
P. Salman,
S. Oh,
G. Bodoky,
G. Kurteva,
C. Volovăț,
V. Moiseyenko,
V. Gorbunova,
...
Joon-Oh Park,
A. Sawaki,
I. Celik,
Heiko Götte,
H. Melezínková,
M. Moehler
|
9 |
2013 |
9
🐢
|
|
🐜
|
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
22 auth.
R. Hofheinz,
F. Wenz,
S. Post,
A. Matzdorff,
S. Lächelt,
J. Hartmann,
L. Müller,
H. Link,
M. Moehler,
E. Kettner,
...
E. Fritz,
U. Hieber,
H. Lindemann,
M. Grunewald,
S. Kremers,
C. Constantin,
M. Hipp,
G. Hartung,
D. Gencer,
P. Kienle,
I. Burkholder,
A. Hochhaus
|
8 |
2012 |
8
🐜
|
|
🐜
|
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
20 auth.
Y. Bang,
E. Ruiz,
E. Cutsem,
K. Lee,
L. Wyrwicz,
M. Schenker,
M. Alsina,
M. Ryu,
H. Chung,
L. Evesque,
...
Salah-Eddin Al-Batran,
Silvia Park,
M. Lichinitser,
N. Boku,
M. Moehler,
Janet Hong,
H. Xiong,
R. Hallwachs,
Ilaria Conti,
J. Taieb
|
8 |
2018 |
8
🐜
|
|
🐜
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
23 auth.
S. Stintzing,
D. Modest,
Lisa Rossius,
M. Lerch,
L. V. von Weikersthal,
T. Decker,
A. Kiani,
U. Vehling‐Kaiser,
S. Al-Batran,
T. Heintges,
...
C. Lerchenmüller,
C. Kahl,
G. Seipelt,
F. Kullmann,
M. Stauch,
W. Scheithauer,
S. Held,
C. Gießen-Jung,
M. Moehler,
A. Jagenburg,
T. Kirchner,
A. Jung,
V. Heinemann
|
8 |
2016 |
8
🐜
|
|
🐜
|
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
28 auth.
S. Al-Batran,
N. Homann,
C. Pauligk,
G. Illerhaus,
U. Martens,
J. Stoehlmacher,
H. Schmalenberg,
K. Luley,
N. Prasnikar,
M. Egger,
S. Probst,
H. Messmann,
M. Moehler,
W. Fischbach,
J. Hartmann,
...
F. Mayer,
H. Höffkes,
M. Koenigsmann,
D. Arnold,
T. Kraus,
Kersten Grimm,
Stefan Berkhoff,
S. Post,
E. Jäger,
W. Bechstein,
U. Ronellenfitsch,
S. Mönig,
R. Hofheinz
|
8 |
2017 |
8
🐜
|
|
🐜
|
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
29 auth.
K. Shitara,
J. Ajani,
M. Moehler,
M. Garrido,
C. Gallardo,
L. Shen,
K. Yamaguchi,
L. Wyrwicz,
T. Skoczylas,
A. Bragagnoli,
Tianshu Liu,
M. Tehfé,
E. Elimova,
R. Brugés,
T. Zander,
...
Sergio Jobim de Azevedo,
R. Kowalyszyn,
R. Pazo-Cid,
M. Schenker,
J. Cleary,
P. Yanez,
K. Feeney,
M. Karamouzis,
V. Poulart,
M. Lei,
H. Xiao,
K. Kondo,
Mingshun Li,
Y. Janjigian
|
8 |
2022 |
8
🐜
|
|
🐢
|
Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer
10 auth.
C. Schimanski,
Stefan Schwald,
N. Simiantonaki,
C. Jayasinghe,
U. Gönner,
Vanessa Wilsberg,
...
T. Junginger,
M. Berger,
P. Galle,
M. Moehler
|
8 |
2005 |
8
🐢
|
|
🐜
|
Chemotherapy for advanced gastric cancer.
8 auth.
A. Wagner,
N. Syn,
M. Moehler,
W. Grothe,
W. Yong,
B. Tai,
...
J. Ho,
S. Unverzagt
|
8 |
2017 |
8
🐜
|
